These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

663 related articles for article (PubMed ID: 19147339)

  • 1. Risk environments and drug harms: a social science for harm reduction approach.
    Rhodes T
    Int J Drug Policy; 2009 May; 20(3):193-201. PubMed ID: 19147339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The drifting city: the role of affect and repair in the development of "Enabling Environments".
    Duff C
    Int J Drug Policy; 2009 May; 20(3):202-8. PubMed ID: 18938069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapping the experience of drug dealing risk environments: an ethnographic case study.
    Fitzgerald JL
    Int J Drug Policy; 2009 May; 20(3):261-9. PubMed ID: 19171472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Putting at risk what we know: reflecting on the drug-using subject in harm reduction and its political implications.
    Moore D; Fraser S
    Soc Sci Med; 2006 Jun; 62(12):3035-47. PubMed ID: 16413645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Theorizing "Big Events" as a potential risk environment for drug use, drug-related harm and HIV epidemic outbreaks.
    Friedman SR; Rossi D; Braine N
    Int J Drug Policy; 2009 May; 20(3):283-91. PubMed ID: 19101131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Public injection settings in Vancouver: physical environment, social context and risk.
    Small W; Rhodes T; Wood E; Kerr T
    Int J Drug Policy; 2007 Jan; 18(1):27-36. PubMed ID: 17689341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of pleasure in harm reduction: perspectives from the history of sexuality.
    Race K
    Int J Drug Policy; 2008 Oct; 19(5):417-23. PubMed ID: 17904347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mutual extraction industry: drug use and the normative structure of social capital in the Russian far north.
    Pilkington H; Sharifullina E
    Int J Drug Policy; 2009 May; 20(3):251-60. PubMed ID: 18954967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 'Individual' harms, Community 'harms': reconciling Indigenous values with drug harm minimisation policy.
    van der Sterren AE; Anderson IP; Thorpe LG
    Drug Alcohol Rev; 2006 May; 25(3):219-25. PubMed ID: 16753645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dilemmas in harm minimization.
    Weatherburn D
    Addiction; 2009 Mar; 104(3):335-9. PubMed ID: 18855811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Casting light on harm reduction: introducing two instruments for analysing contradictions between harm reduction and 'non-harm reduction'.
    Jourdan M
    Int J Drug Policy; 2009 Nov; 20(6):514-20. PubMed ID: 19349155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erasing pleasure from public discourse on illicit drugs: on the creation and reproduction of an absence.
    Moore D
    Int J Drug Policy; 2008 Oct; 19(5):353-8. PubMed ID: 17728122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving health and social care relationships for harm reduction.
    Allman D; Myers T; Schellenberg J; Strike C; Cockerill R; Cavalieri W
    Int J Drug Policy; 2007 May; 18(3):194-203. PubMed ID: 17689366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of environmental modifiers of the relationship between substance use and harm.
    Rehn J; Fischer B; Graham K; Haydon E; Mann RE; Room R
    Addiction; 2004 Jun; 99(6):663-6. PubMed ID: 15139864
    [No Abstract]   [Full Text] [Related]  

  • 15. The ethical, legal and social context of harm reduction.
    Pauly B; Goldstone I; McCall J; Gold F; Payne S
    Can Nurse; 2007 Oct; 103(8):19-23. PubMed ID: 17990401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Social ecology of the drug problem].
    Tretter F
    Gesundheitswesen; 1998 Aug; 60 Suppl 1():S47-55. PubMed ID: 9816761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal timing of use reduction vs. harm reduction in a drug epidemic model.
    Caulkins JP; Tragler G; Wallner D
    Int J Drug Policy; 2009 Nov; 20(6):480-7. PubMed ID: 19361975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harm reduction and the global drug control regime: contemporary problems and future prospects.
    Bewley-Taylor DR
    Drug Alcohol Rev; 2004 Dec; 23(4):483-9. PubMed ID: 15763753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding post 9/11 drug control policy and politics in Central Asia.
    Latypov A
    Int J Drug Policy; 2009 Sep; 20(5):387-91. PubMed ID: 19121928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From harm reduction to human rights: bringing liberalism back into drug reform debates.
    Hathaway AD
    Drug Alcohol Rev; 2002 Dec; 21(4):397-404. PubMed ID: 12537711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.